Abstract
Risk assessment of breast cancer (BC) seeks to enhance individualized screening and prevention strategies. BC risk informs healthy individuals of the short- and long-term likelihood of cancer development, also enabling detection of existing BC. Recent mammographic-based deep learning (DL) risk models outperform traditional risk factor-based models and achieve state-of-the-art (SOTA) at short-term risk prediction, but mainly use single-time exams, which seem to rely more on detecting existing lesions. We present a novel temporospatial and explainable deep learning risk model, the Multi-Time Point Breast Cancer Risk Model (MTP-BCR), which learns from longitudinal mammography data to identify subtle changes in breast tissue that may signal future malignancy. Utilizing a large in-house dataset of 171,168 screening mammograms from 42,792 consecutive exams involving 9,133 women, our model demonstrates a significant improvement in long-term (10-year) risk prediction with an area under the receiver operating characteristics (AUC) of 0.80, outperforming the traditional BCSC 10-year risk model and other SOTA methods at 5-year AUC in various screening cohorts. Furthermore, MTP-BCR provides unilateral breast-level predictions, achieving AUCs up to 0.81 and 0.77 for 5-year risk and 10-year risk assessments, respectively. The heatmaps derived from our model may help clinicians better understand the progression from normal tissue to cancerous growth, enhancing interpretability in breast cancer risk assessment.
Teaser MTP-BCR model uses multi-time points mammograms and rich risk factors to predict 10-year breast cancer risk more accurately.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was funded by Chinese Scholarship Council scholarship (CSC)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Netherlands Cancer Institute(NKI) institutional review board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The inhouse dataset is used under license to the respective hospital system for the current study and is not publicly available.